GOTHENBURG, SWEDEN / ACCESSWIRE / January 25, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Fourth quarter 2023 (October 1 - December 31)…
NMQF Releases Report that 56% of People of Color Live in Carcinogenic Environments; Announce Public-Private Collaboration to Address ProblemWashington, D.C.--(Newsfile…
GOTHENBURG, SE / ACCESSWIRE / January 24, 2024 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL)(FRA:3XV) In a recently published [1] clinical…
The follow-on funding is a draw down from the $10 million private placement agreement entered into September 25 2023.Use of…
* New clinical trials have confirmed that Thermobalancing therapy with Dr Allen's Device is the first natural treatment option for…
HAMILTON, BERMUDA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Altamira’s polyKRASmut siRNA shown to knock down at least 65-91% of KRAS…
LOS ANGELES, CA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), a…
Tailored Vaccines: With the AI-Immunology™ enabled discovery of these novel types of cancer vaccine targets, designing personalized and precision vaccine…
Velocity President and Chief Executive, Dr Paul Evans Velocity President and Chief Executive, Dr Paul Evans • nmible’s solution expected…
- Initiation of CX-2051 Phase 1 clinical study in EpCAM positive tumors including colorectal cancer anticipated in 1H 2024 -…